SBIR-STTR Award

Attenuating Reperfusion Injury With Combined Hypothermia And Gradual Reperfusion.
Award last edited on: 9/9/14

Sponsored Program
SBIR
Awarding Agency
NIH : NHLBI
Total Award Amount
$299,761
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Thomas L Merrill

Company Information

FocalCool LLC

107 Gilbreth Parkway
Mullica Hill, NJ 08062
   (856) 256-4301
   jakers@focalcool.com
   www.focalcool.com
Location: Single
Congr. District: 02
County: Gloucester

Phase I

Contract Number: 1R43HL117403-01
Start Date: 9/1/13    Completed: 8/31/14
Phase I year
2013
Phase I Amount
$299,761
The primary care goal during a heart attack is to quickly restore blood perfusion. Reperfusion, however, is paradoxical, while it enables organ survival; it also enables destructive biochemical processes. While numerous adjunctive therapies for acute myocardial infarctions (AMI) have been studied, innovative combination therapies are needed. Both hypothermia and gradual reperfusion have shown benefit in terms of saving heart tissue following ischemia-reperfusion. The overall goal of this work is to combine these two techniques for additive and perhaps synergistic benefits for improving AMI outcomes. Specific Aims: 1) Develop a combination therapy device that precisely controls reperfusion flow as well as tissue cooling and re-warming. 2) Demonstrate that the proposed combination therapy technology has the ability to carefully and safely control both reperfusion and tissue temperature and provides tissue salvage benefit in a large animal translational ischemia-reperfusion model. To achieve aim #1, a fixed set of design input requirements and feasibility points will be developed, five fully characterized and robust device prototypes will be created ready for in vivo testing, and an optimal operational protocol based on tissue cooling ability and potential efficacy for in vivo testing will be selected. For aim #2, the optimal operational protocl will be tested in a large animal ischemia-reperfusion model. These results will show that the protocol is safe and effective at reducing tissue damage, demonstrating that there is a potential for clinically relevant tissue salvage. Relevance: Approximately 110,000 people each year in the U.S. have an emergency angioplasty procedure. According to the AHA 2010 Statistics, 20% of first time heart attack victims die within one year of the event. FocalCool, LLC's goal is to improve emergency angioplasty patient outcomes by reducing reperfusion injury through safe and effective use of controlled reperfusion hypothermia. If Phase I goals to demonstrate safety, cooling ability, and tissue salvage feasibility of the joint technology are successful, Phase II wok will freeze the design for GLP animal testing and an IDE application and demonstrate efficacy of tissue salvage in a translational preclinical model.

Public Health Relevance Statement:


Public Health Relevance:
While percutanous coronary intervention (PCI) is effective at re-establishing perfusion to formerly blocked areas of the heart, there are currently no approved therapeutic treatments or devices on the market for myocardial reperfusion injury reduction. FocalCool, LLC seeks to develop an easy-to-use combination technology that carefully controls reperfusion blood flow as well as blood temperature to safely and quickly deliver cooled blood directly to the heart as an adjunctive treatment during PCI. If the proposed aims are achieved, a reperfusion injury reduction prototype device will be realized, with little change to today's care path, preserving more healthy heart tissue post PCI for improved patient outcomes.

NIH Spending Category:
Bioengineering; Cardiovascular; Heart Disease; Heart Disease - Coronary Heart Disease

Project Terms:
Acute myocardial infarction; Affect; Angioplasty; Animal Model; Animal Testing; Animals; Area; attack victim; Attenuated; base; Biochemical Process; Blood; Blood flow; Canis familiaris; Caring; Catheters; clinically relevant; Combined Modality Therapy; Controlled Study; Coronary; Coronary artery; Custom; design; Devices; Educational workshop; Emergency Situation; Event; Family suidae; Freezing; Goals; Heart; improved; in vivo; Infarction; innovation; Intervention; Ischemia; Joints; Legal patent; Marketing; Mechanics; Modeling; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; National Heart, Lung, and Blood Institute; natural hypothermia; Organ; Organ Survival; Outcome; Patients; percutaneous coronary intervention; Performance; Perfusion; perfusion (blood); Phase; Pre-Clinical Model; pressure; Primary Health Care; Procedures; Protocols documentation; prototype; public health relevance; Ramp; Reperfusion Injury; Reperfusion Therapy; Risk; Safety; statistics; System; Techniques; technological innovation; Technology; Temperature; Test Result; Testing; Therapeutic; Time; Tissues; Universities; Work

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----